Literature DB >> 19659650

Cumulative incidence of and predictive factors for lung cancer in IPF.

Yuichi Ozawa1, Takafumi Suda, Tateaki Naito, Noriyuki Enomoto, Dai Hashimoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Hirotoshi Nakamura, Kingo Chida.   

Abstract

BACKGROUND AND
OBJECTIVE: Previous studies have indicated a high incidence of lung cancer in IPF, and some have identified its risk factors. However, those studies were retrospective and the clinical characteristics of IPF patients developing lung cancer were evaluated only when those patients had developed the cancer. The true cumulative incidence of lung cancer after the diagnosis of IPF and its predictive factors at the initial diagnosis of IPF remain unknown. The present study was conducted to elucidate the cumulative incidence and risk factors for lung cancer in IPF patients by retrospective longitudinal cohort analysis.
METHODS: The study group consisted of 103 IPF patients without lung cancer at the time of their initial diagnosis. The cumulative incidence of lung cancer was estimated using the Kaplan-Meier method. The strength of association between several variables present at the initial diagnosis of IPF and the development of lung cancer was assessed using Cox proportional hazards regression analysis.
RESULTS: A total of 21 (20.4%) patients with IPF developed lung cancer during the observation period. The cumulative incidence rate of lung cancer increased as the duration of follow up increased (3.3%, 15.4% and 54.7% at 1, 5 and 10 years, respectively). Univariate Cox proportional hazards regression analysis showed that age and smoking at the initial diagnosis of IPF were significantly associated with lung cancer. Multivariate Cox proportional hazards regression analysis indicated that age at initial diagnosis was an independent significant factor predicting lung cancer.
CONCLUSIONS: The cumulative incidence of lung cancer increased over time and age at diagnosis of IPF was independently associated with development of lung cancer.

Entities:  

Mesh:

Year:  2009        PMID: 19659650     DOI: 10.1111/j.1440-1843.2009.01547.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  83 in total

1.  Clinical results of sublobar resection versus lobectomy or more extensive resection for lung cancer patients with idiopathic pulmonary fibrosis.

Authors:  Seok Joo; Dong Kwan Kim; Hee Je Sim; Geun Dong Lee; Su Kyung Hwang; Sehoon Choi; Hyeong Ryul Kim; Yong-Hee Kim; Seung-Il Park
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

Review 2.  Idiopathic pulmonary fibrosis in East Asian.

Authors:  Changbo Sun; Yanbin Sun; Hui Shen; Chunlu Yang; Shun Xu
Journal:  Intractable Rare Dis Res       Date:  2017-05

Review 3.  Lung cancer and interstitial lung disease: a literature review.

Authors:  Jean-Marc Naccache; Quentin Gibiot; Isabelle Monnet; Martine Antoine; Marie Wislez; Christos Chouaid; Jacques Cadranel
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

4.  Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung.

Authors:  Takuya Ueda; Keiju Aokage; Hiroyoshi Nishikawa; Shinya Neri; Hiroshi Nakamura; Masato Sugano; Kenta Tane; Tomohiro Miyoshi; Motohiro Kojima; Satoshi Fujii; Takeshi Kuwata; Atsushi Ochiai; Masahiko Kusumoto; Kenji Suzuki; Masahiro Tsuboi; Genichiro Ishii
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-12       Impact factor: 4.553

5.  From bad to worse: when lung cancer complicates idiopathic pulmonary fibrosis.

Authors:  Stephen B Strock; Jonathan K Alder; Daniel J Kass
Journal:  J Pathol       Date:  2018-02-14       Impact factor: 7.996

6.  Retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease.

Authors:  Yuto Yasuda; Takashi Nomizo; Hiroaki Ozasa; Tomoko Funazo; Takahiro Tsuji; Hironori Yoshida; Yuichi Sakamori; Hiroki Nagai; Tomohiro Handa; Takeshi Kubo; Young Hak Kim
Journal:  Mol Clin Oncol       Date:  2017-08-11

7.  Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects.

Authors:  Elena Bargagli; Viola Bonti; Katia Ferrari; Elisabetta Rosi; Alessandra Bindi; Maurizio Bartolucci; Moroni Chiara; Luca Voltolini
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

8.  Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease.

Authors:  Hideyuki Niwa; Yoshiro Nakahara; Masanori Yokoba; Hisashi Mitsufuji; Jiichiro Sasaki; Noriyuki Masuda
Journal:  Mol Clin Oncol       Date:  2017-08-03

Review 9.  New perspectives on management of idiopathic pulmonary fibrosis.

Authors:  Silvia Puglisi; Sebastiano Emanuele Torrisi; Virginia Vindigni; Riccardo Giuliano; Stefano Palmucci; Massimiliano Mulè; Carlo Vancheri
Journal:  Ther Adv Chronic Dis       Date:  2016-02-01       Impact factor: 5.091

10.  A review of current and novel therapies for idiopathic pulmonary fibrosis.

Authors:  Rokhsara Rafii; Maya M Juarez; Timothy E Albertson; Andrew L Chan
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.